Predictive Factors Among Clinicopathological Characteristics for Sentinel Lymph Node Metastasis in T1-T2 Breast Cancer.
breast cancer
impaired glucose tolerance
nipple-tumor distance
predictive factor
sentinel lymph node metastasis
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
10
2020
accepted:
23
11
2020
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
21
1
2021
Statut:
epublish
Résumé
The axillary lymph node status is an important prognostic factor of breast cancer. This study explores the predictive factors for sentinel lymph node (SLN) metastasis among the preoperative clinicopathological features, including impaired glucose tolerance (IGT). This study comprised patients diagnosed with breast cancer who underwent surgery at Nagasaki Harbor Medical Center between April 2014 and December 2019. The factors assessed using univariate and multivariate analyses were the clinicopathological data of these cancers, including the patient age, gender, menstrual status, breast or ovarian cancer family history, body mass index, glycosylated hemoglobin, clinical tumor size, nipple-tumor distance (NTD), tumor histology, histological grade, node status, estrogen receptor, progesterone receptor, human epidermal growth factor receptor type 2 status, and Ki67 labeling index. In the cohort of 313 cases, the ratio of SLN metastasis was 17.3%. A univariate analysis found that the tumor size, NTD, IGT, and clinical tumor stage were associated with SLN metastasis. In a multivariable analysis, the tumor size, NTD, and IGT were associated with SLN metastasis. The receiver operating characteristic curve showed a sensitivity and specificity of 61.1% and 65.6%, respectively, at a cut-off of 1.7 cm for the tumor size (area under the curve [AUC]: 0.664; 95% confidence interval: 0.592-0.736), and a sensitivity and specificity of 60.4% and 62.9%, respectively, at a cut-off of 2.0 cm for NTD (AUC: 0.651; 95% confidence interval: 0.571-0.731) to predict the risk of SLN metastasis. T1 and T2 breast cancer patients with a larger tumor size, tumor located closer to the nipple, and IGT have a higher risk of SLN metastases than others.
Sections du résumé
BACKGROUND
BACKGROUND
The axillary lymph node status is an important prognostic factor of breast cancer. This study explores the predictive factors for sentinel lymph node (SLN) metastasis among the preoperative clinicopathological features, including impaired glucose tolerance (IGT).
METHODS
METHODS
This study comprised patients diagnosed with breast cancer who underwent surgery at Nagasaki Harbor Medical Center between April 2014 and December 2019. The factors assessed using univariate and multivariate analyses were the clinicopathological data of these cancers, including the patient age, gender, menstrual status, breast or ovarian cancer family history, body mass index, glycosylated hemoglobin, clinical tumor size, nipple-tumor distance (NTD), tumor histology, histological grade, node status, estrogen receptor, progesterone receptor, human epidermal growth factor receptor type 2 status, and Ki67 labeling index.
RESULTS
RESULTS
In the cohort of 313 cases, the ratio of SLN metastasis was 17.3%. A univariate analysis found that the tumor size, NTD, IGT, and clinical tumor stage were associated with SLN metastasis. In a multivariable analysis, the tumor size, NTD, and IGT were associated with SLN metastasis. The receiver operating characteristic curve showed a sensitivity and specificity of 61.1% and 65.6%, respectively, at a cut-off of 1.7 cm for the tumor size (area under the curve [AUC]: 0.664; 95% confidence interval: 0.592-0.736), and a sensitivity and specificity of 60.4% and 62.9%, respectively, at a cut-off of 2.0 cm for NTD (AUC: 0.651; 95% confidence interval: 0.571-0.731) to predict the risk of SLN metastasis.
CONCLUSION
CONCLUSIONS
T1 and T2 breast cancer patients with a larger tumor size, tumor located closer to the nipple, and IGT have a higher risk of SLN metastases than others.
Identifiants
pubmed: 33469365
doi: 10.2147/CMAR.S284922
pii: 284922
pmc: PMC7810586
doi:
Types de publication
Journal Article
Langues
eng
Pagination
215-223Informations de copyright
© 2021 Minami et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Cancer. 2005 Feb 1;103(3):492-500
pubmed: 15612028
Cancer Sci. 2013 Jul;104(7):965-76
pubmed: 23879470
JAMA. 2011 Feb 9;305(6):569-75
pubmed: 21304082
Lancet Oncol. 2007 Oct;8(10):881-8
pubmed: 17851130
Lancet Oncol. 2018 Oct;19(10):1385-1393
pubmed: 30196031
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Am J Clin Oncol. 2013 Feb;36(1):20-3
pubmed: 22157215
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Oncologist. 2016 Sep;21(9):1041-9
pubmed: 27388232
Breast. 2013 Jun;22(3):357-61
pubmed: 23022046
Medicine (Baltimore). 2019 Oct;98(40):e17481
pubmed: 31577783
Cancer Metab. 2016 Apr 06;4:7
pubmed: 27054036
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Diabetes Metab Res Rev. 2017 Jan;33(1):
pubmed: 27184049
Clin Anat. 2009 Jul;22(5):531-6
pubmed: 19484798
Diabetes Care. 2010 Jul;33(7):1674-85
pubmed: 20587728
Cancer Manag Res. 2019 Apr 09;11:2915-2925
pubmed: 31040717
N Engl J Med. 1998 Oct 1;339(14):941-6
pubmed: 9753708
Springerplus. 2016 Feb 03;5:114
pubmed: 26885467
Med Sci Monit. 2017 Aug 25;23:4102-4108
pubmed: 28839123
Lancet Oncol. 2006 Dec;7(12):983-90
pubmed: 17138219
Diabetes Care. 2010 Jan;33 Suppl 1:S11-61
pubmed: 20042772
Ann Surg Oncol. 2011 Oct;18(11):3174-80
pubmed: 21861233
PLoS One. 2020 May 5;15(5):e0232581
pubmed: 32369516
CA Cancer J Clin. 2010 Jul-Aug;60(4):207-21
pubmed: 20554718